Saturday 17 October 2026
Export HSCS’s income statement to Excel — free account
HeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025. In the quarter to July 2026, revenue fell 46.2%, EPS grew 45.6% and free cash flow grew 18.2%, each against the same quarter a year earlier.
3.02
0.16
−5.03%
Follow HSCS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to April
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 78.00 | 14.50 | 2.36 | 2.01 | 1.63 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | 600.00 | 395.00 | 18.50 | 6.47 | 5.25 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 13 | 12 | 12 | 15 | 15 | 14 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Gross margin, % | — | — | — | (71.81) | 58.20 | 45.14 | 46.15 | 67.20 | 56.82 | 60.47 | |||||
| EBT | — | — | — | (4) | (2) | (5) | (6) | (7) | (9) | (9) | |||||
| EBT margin, % | — | — | — | (5,936.29) | (9,578.91) | (33,529.86) | (122,198.08) | (35,511.83) | (199,209.09) | (212,602.33) | |||||
| Net income | — | — | — | (4) | (2) | (5) | (6) | (7) | (9) | (9) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.01 | 0.77 | 0.43 | 0.07 | 0.05 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.47) | (74.00) | (145.48) | (80.00) | (19.00) | (9.34) | (3.48) | |||||
| Cash flow | — | — | — | (0.48) | (74.09) | (109.76) | (72.62) | (17.22) | (7.90) | (2.83) | |||||
| Capex | — | — | — | 0.00 | (0.02) | (0.06) | (0.23) | (0.36) | (0.03) | (0.02) | |||||
| Free cash flow | — | — | — | (0.48) | (74.11) | (109.82) | (72.85) | (17.58) | (7.93) | (2.85) | |||||
| Book value | — | — | — | 0.04 | (57.69) | (182.40) | 2.90 | 20.76 | 0.22 | 0.09 | |||||
| Shares, m | — | — | — | 8 | 0 | 0 | 0 | 0 | 1 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | 0.00 | 0.00 | 0.00 | 722.34 | 157.43 | 159.88 | 223.56 | |||||
| P/B | — | — | — | 0.00 | 0.00 | 0.00 | 29.18 | 0.44 | 16.08 | 22.73 | |||||
| EV/Sales | — | — | — | 0.00 | 0.00 | 0.00 | 624.44 | (88.72) | 121.11 | 180.54 | |||||
| EV/FCF | — | — | — | (2.58) | (2.58) | (2.58) | (1.00) | 0.30 | (0.33) | (0.55) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (2) | (4) | (6) | (6) | (7) | (7) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (4) | (2) | (4) | (6) | (6) | (7) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 1 | (2) | 1 | 6 | (2) | (2) | ||||
| Total debt | — | — | — | 1 | 3 | 4 | 1 | — | — | — | |||||
| Net debt | — | — | — | 0 | 2 | 4 | (1) | (6) | (1) | (2) | |||||
| Shareholders’ equity | — | — | — | 0 | (2) | (6) | 0 | 7 | 0 | 0 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (126.29) | (240.41) | (236.37) | (103.28) | (127.72) | (192.75) | ||||
| ROIC | — | — | — | 0.00 | (1,369.82) | 0.00 | 0.00 | (261.05) | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | 307.49 | 121.22 | 218.13 | (175.04) | (233.06) | (4,252.05) | |||||
Negative figures in brackets.
Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 1 Oct 2026
Charts ten years each
HeartSciences Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PAVM PAVmed Inc. | $19.4M | — (loss-making) | — (loss-making) | +450.00% (above 0%: growing) | n/m | −125.63% (below 0%: shrinking) | (269.70%) | (21,278.79%) | Compare |
| BDMD Baird Medical Investment Holdings Limited | $19.2M | — (loss-making) | — | — | n/m | −598.12% (below 0%: shrinking) | — | — | Compare |
| LFWD Lifeward Ltd. | $17.2M | — (loss-making) | — (loss-making) | +15.71% (above 0%: growing) | n/m | −52.77% (below 0%: shrinking) | 40.90% | (62.69%) | Compare |
| ALUR Allurion Technologies, Inc. | $16.7M | — (loss-making) | — (loss-making) | −47.19% (below 0%: shrinking) | n/m | +65.98% (above 0%: growing) | 41.70% | (126.60%) | Compare |
| HSCS HeartSciences Inc. | $15.4M | — (loss-making) | — (loss-making) | −46.15% (below 0%: shrinking) | n/m | +18.18% (above 0%: growing) | 61.90% | (139,957.14%) | |
| IRIX IRIDEX Corporation | $14.5M | — (loss-making) | — (loss-making) | −7.41% (below 0%: shrinking) | n/m | +130.24% (above 0%: growing) | 34.19% | (8.19%) | Compare |
| RBOT Vicarious Surgical Inc. | $14.3M | — (loss-making) | — | — | n/m | +47.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SINT SINTX TECHNOLOGIES, INC. | $13.4M | — (loss-making) | — (loss-making) | +199.34% (above 0%: growing) | n/m | −38.60% (below 0%: shrinking) | 61.50% | (638.94%) | Compare |
| PETV PetVivo Holdings, Inc. | $12.9M | — (loss-making) | — (loss-making) | +13.48% (above 0%: growing) | n/m | +40.13% (above 0%: growing) | 66.14% | (476.54%) | Compare |
| Median of peers | $15.6M | — | — | +14.60% | — | +0.76% | 40.90% | (126.60%) |
HeartSciences Inc. (HSCS) key facts
- Concern: HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025.
- HeartSciences Inc. (HSCS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HSCS traded at $3.02, a market capitalization of $15.4 million.
- Return on equity was −4,252.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −27.87 (distress zone) for fiscal 2026.